Radiodermatitis
Drug research and approvals for radiodermatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 27 studies of radiodermatitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 27
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Thalidomide for Preventing Radiation-Induced Dermatitis in Breast Cancer PatientsNCT07933653 · Not applicable · First Affiliated Hospital of Guangxi Medical University · starts Nov 12, 2026
- A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation…NCT07918989 · Phase 2 · Memorial Sloan Kettering Cancer Center · starts Oct 30, 2026
- Adapalene Gel for Acute Radiation-Induced Skin InjuryNCT07886320 · Early Phase 1 · Yunnan Cancer Hospital · starts Mar 1, 2026
- Using Silverlon® for Head and Neck Patients With TracheostomiesNCT07856732 · Phase 1 · State University of New York - Upstate Medical University · starts Aug 30, 2026
- Topical Boswellia Serrata 2% to Prevent Radiation Dermatitis in Head and Neck CancerNCT07778290 · Not applicable · Youssef Hashem Hafez · starts Aug 18, 2026
- Mepitel Film BreastNCT07729423 · Not reported · National University Hospital, Singapore · starts Nov 12, 2025
- Superoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck CancerNCT07704372 · Phase 2 · West China Hospital · starts Sep 28, 2026
- Akkermansia Muciniphila (AKK) for Radiation-Induced Skin InjuryNCT07635277 · Phase 1 · West China Hospital · starts Jun 7, 2026
- Polarized Light Therapy for Radiation Dermatitis in Breast CancerNCT07600957 · Not applicable · Beni-Suef University · starts May 21, 2026
Phase 2 7
- ChlorhexidineCell membrane inhibitor
- CalcipotrieneVitamin D receptor agonist
- MupirocinIsoleucyl-tRNA synthetase inhibitor
- Mometasone furoateGlucocorticoid receptor agonist
- Polyethylene glycolOsmotic laxative
- Chamomile
- Curcumin
Phase 1 or earlier 4
- NorepinephrineAdrenergic receptor agonist
- SapropterinPhenylalanine-4-hydroxylase activator
- LUT-014
- Petrolatum
How its trials ended
119 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 25 whose ending is known, 16% met their primary endpoint, 4% missed it and 80% stopped early.
- Completed, result not reported5647%
- Status unknown2118%
- Ongoing1714%
- Stopped: other or unclear119%
- Met its primary endpoint43%
- Stopped: enrollment or feasibility43%
- Stopped: lack of efficacy22%
- Stopped: sponsor or business decision22%
- Missed its primary endpoint11%
- Stopped: funding11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA